About Omeros (NASDAQ:OMER)
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from its PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. Its PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.
Industry, Sector and Symbol
Industry MED PRODS
Trailing P/E Ratio-9.94863291766737
Forward P/E Ratio-15.32
Sales & Book Value
Annual Sales$64.83 million
Price / Sales8.67
Price / CashN/A
Book Value($0.06) per share
Price / Book-194.00
Return on EquityN/A
Return on Assets-40.03%
Omeros (NASDAQ:OMER) Frequently Asked Questions
What is Omeros' stock symbol?
Omeros trades on the NASDAQ under the ticker symbol "OMER."
How were Omeros' earnings last quarter?
Omeros Co. (NASDAQ:OMER) released its quarterly earnings data on Thursday, March, 1st. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.03. The biopharmaceutical company earned $13.76 million during the quarter, compared to analyst estimates of $21.94 million. The business's revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.45) EPS. View Omeros' Earnings History.
When will Omeros make its next earnings announcement?
Where is Omeros' stock going? Where will Omeros' stock price be in 2018?
8 equities research analysts have issued 1-year target prices for Omeros' stock. Their predictions range from $4.00 to $75.00. On average, they anticipate Omeros' share price to reach $29.72 in the next twelve months. View Analyst Ratings for Omeros.
What are Wall Street analysts saying about Omeros stock?
Here are some recent quotes from research analysts about Omeros stock:
- 1. Maxim Group analysts commented, "Omeros reported 4Q17 financial results and Omidria sales were $13.8M vs. $21.7M in the prior quarter. BUT… in terms of units (no. of vials shipped), it is our understanding that the levels are flat with the prior period. In other words, this is partly a revenue recognition issue, triggered by the change in pass through status. The company recorded a net loss of $16.6M and ended the period with $84M in cash and another $17M in accounts receivable." (3/2/2018)
- 2. According to Zacks Investment Research, "Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. " (3/1/2018)
- 3. Cantor Fitzgerald analysts commented, "Omeros announced that it received breakthrough therapy designation for its MASP-2 inhibitor, OMS721, for the treatment of IgA nephropathy (IgAN)." (6/13/2017)
Who are some of Omeros' key competitors?
Some companies that are related to Omeros include Owens & Minor (OMI), Luminex (LMNX), K2M Group (KTWO), Cardiovascular Systems (CSII), Eagle Pharmaceuticals (EGRX), Cerus (CERS), LeMaitre Vascular (LMAT), Cryolife (CRY), AtriCure (ATRC), Invacare (IVC), STAAR Surgical (STAA), Meridian Bioscience (VIVO), AngioDynamics (ANGO), PetIQ (PETQ), Lantheus (LNTH), Tactile Systems Technology (TCMD), Mesa Laboratories (MLAB) and Viewray (VRAY).
Who are Omeros' key executives?
Omeros' management team includes the folowing people:
- Gregory A. Demopulos M.D., Chairman of the Board, President, Chief Executive Officer (Age 58)
- Michael A. Jacobsen, Chief Accounting Officer, Vice President - Finance, Treasurer (Age 58)
- Marcia S. Kelbon J.D., Vice President - Patent, General Counsel, Secretary (Age 57)
- Thomas J. Cable, Lead Independent Director (Age 77)
- Peter A. Demopulos M.D., Director (Age 61)
- Ray Aspiri, Independent Director (Age 78)
- Arnold C. Hanish, Independent Director (Age 69)
- Leroy E. Hood M.D., Ph.D., Independent Director (Age 78)
Has Omeros been receiving favorable news coverage?
Media coverage about OMER stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Omeros earned a news sentiment score of 0.21 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.46 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Omeros' major shareholders?
Omeros' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Ingalls & Snyder LLC (11.12%), Cpwm LLC (2.26%), Capital Analysts LLC (1.23%), Geode Capital Management LLC (0.82%), Tocqueville Asset Management L.P. (0.60%) and Bank of New York Mellon Corp (0.45%). Company insiders that own Omeros stock include Gregory A Md Demopulos, Marcia S Kelbon, Michael A Jacobsen and Thomas J Cable. View Institutional Ownership Trends for Omeros.
Which major investors are selling Omeros stock?
OMER stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., Allianz Asset Management GmbH, Goldman Sachs Group Inc., Bank of New York Mellon Corp, Raymond James & Associates, Metropolitan Life Insurance Co. NY, TIAA CREF Investment Management LLC and Candriam Luxembourg S.C.A.. Company insiders that have sold Omeros company stock in the last year include Michael A Jacobsen and Thomas J Cable. View Insider Buying and Selling for Omeros.
Which major investors are buying Omeros stock?
OMER stock was acquired by a variety of institutional investors in the last quarter, including Capital Analysts LLC, Ingalls & Snyder LLC, First Trust Advisors LP, Deutsche Bank AG, Virtus Fund Advisers LLC, Millennium Management LLC, Wells Fargo & Company MN and Fox Run Management L.L.C.. View Insider Buying and Selling for Omeros.
How do I buy shares of Omeros?
Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Omeros' stock price today?
One share of OMER stock can currently be purchased for approximately $11.64.
How big of a company is Omeros?
Omeros has a market capitalization of $529.21 million and generates $64.83 million in revenue each year. The biopharmaceutical company earns $-53,480,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis. Omeros employs 173 workers across the globe.
How can I contact Omeros?
Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at 206-676-5000.
MarketBeat Community Rating for Omeros (OMER)MarketBeat's community ratings are surveys of what our community members think about Omeros and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Omeros (NASDAQ:OMER) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.75||2.88||2.88||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
3 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
|Consensus Price Target: ||$29.72||$31.57||$36.17||$33.38|
|Price Target Upside: ||155.29% upside||186.75% upside||87.20% upside||57.06% upside|
Omeros (NASDAQ:OMER) Consensus Price Target History
Omeros (NASDAQ:OMER) Analyst Ratings History
(Data available from 3/21/2016 forward)
Omeros (NASDAQ:OMER) Earnings History and Estimates Chart
Omeros (NASDAQ OMER) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/1/2018||Q4 2017||($0.22)||($0.25)||$21.94 million||$13.76 million||View||Listen|
|11/9/2017||Q3 2017||($0.34)||($0.16)||$17.82 million||$21.66 million||View||N/A|
|8/8/2017||Q2 2017||($0.35)||($0.23)||$14.63 million||$17.15 million||View||Listen|
|5/10/2017||Q1 2017||($0.35)||($0.34)||$13.32 million||$12.26 million||View||N/A|
|3/16/2017||Q4 2016||($0.48)||($0.20)||$12.71 million||$12.91 million||View||N/A|
|11/9/2016||Q3 2016||($0.40)||($0.34)||$11.64 million||$11.30 million||View||Listen|
|8/9/2016||Q216||($0.50)||($0.32)||$9.80 million||$10.00 million||View||Listen|
|5/10/2016||Q116||($0.43)||($0.54)||$8.79 million||$7.40 million||View||Listen|
|3/8/2016||Q415||($0.53)||($0.52)||$5.35 million||$6.66 million||View||Listen|
|11/9/2015||Q315||($0.47)||($0.46)||$7.97 million||$3.30 million||View||Listen|
|8/10/2015||Q215||($0.56)||($0.44)||$2.86 million||$3.20 million||View||Listen|
|5/11/2015||Q115||($0.63)||($0.51)||$0.15 million||$0.39 million||View||Listen|
|3/16/2015||Q4||($0.62)||($0.61)||$0.15 million||$0.18 million||View||Listen|
|11/10/2014||Q114||($0.59)||($0.54)||$0.43 million||$0.21 million||View||N/A|
|8/11/2014||Q2||($0.56)||($0.53)||$0.37 million||$0.45 million||View||N/A|
|5/12/2014||Q1||($0.45)||($0.45)||$0.45 million||$0.10 million||View||N/A|
|3/13/2014||Q413||($0.38)||($0.05)||$0.17 million||$1.70 million||View||N/A|
|11/7/2013||Q313||($0.44)||($0.46)||$0.14 million||$0.20 million||View||N/A|
|8/9/2013||Q213||($0.38)||($0.48)||$1.19 million||$0.14 million||View||N/A|
|5/10/2013||Q1 2013||($0.39)||($0.40)||$1.39 million||$1.10 million||View||N/A|
|3/18/2013||($0.35)||($0.30)||$1.49 million||$1.58 million||View||N/A|
|11/9/2012||Q312||($0.34)||($0.51)||$1.42 million||$1.40 million||View||N/A|
Omeros (NASDAQ:OMER) Earnings Estimates
2018 EPS Consensus Estimate: ($0.25)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Omeros (NASDAQ:OMER)
No dividend announcements for this company have been tracked by MarketBeat.com
Omeros (NASDAQ OMER) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 12.10%
Institutional Ownership Percentage: 48.56%
Omeros (NASDAQ OMER) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/3/2018||Michael A Jacobsen||VP||Sell||1,020||$22.45||$22,899.00||8,520|| |
|6/16/2017||Michael A Jacobsen||VP||Sell||12,000||$24.95||$299,400.00||19,500|| |
|6/15/2017||Michael A Jacobsen||VP||Sell||24,000||$21.20||$508,800.00||2,650|| |
|4/12/2017||Thomas J Cable||Director||Sell||3,000||$16.49||$49,470.00||40,067|| |
|12/7/2016||Gregory A Md Demopulos||CEO||Sell||306,124||$10.66||$3,263,281.84||1,987,025|| |
|12/6/2016||Gregory A Md Demopulos||CEO||Sell||102,040||$10.80||$1,102,032.00||1,987,025|| |
|12/5/2016||Gregory A Md Demopulos||CEO||Sell||102,040||$10.71||$1,092,848.40||1,987,025|| |
|12/2/2016||Gregory A Md Demopulos||CEO||Sell||306,120||$11.58||$3,544,869.60||1,801,381|| |
|9/15/2016||Marcia S Kelbon||VP||Sell||16,000||$10.91||$174,560.00||179,597|| |
|8/15/2016||Marcia S Kelbon||VP||Sell||15,900||$11.56||$183,804.00||179,497|| |
|7/15/2016||Marcia S Kelbon||VP||Sell||15,900||$11.50||$182,850.00||179,497|| |
|6/15/2016||Marcia S Kelbon||VP||Sell||15,900||$11.42||$181,578.00||179,497|| |
|5/16/2016||Marcia S Kelbon||VP||Sell||15,900||$9.94||$158,046.00||179,497|| |
|4/15/2016||Marcia S Kelbon||VP||Sell||15,900||$15.18||$241,362.00||179,497|| |
|3/24/2016||Thomas J Cable||Director||Sell||2,000||$14.81||$29,620.00||49,467|| |
|12/22/2015||Marcia S. Kelbon||VP||Sell||15,900||$15.00||$238,500.00||138,426|| |
|9/4/2015||Peter A Md Demopulos||Director||Buy||3,962||$12.68||$50,238.16||185,182|| |
|7/15/2015||Thomas J Cable||Director||Sell||2,000||$18.78||$37,560.00|| |
|3/24/2015||Thomas J Cable||Director||Sell||2,000||$24.50||$49,000.00|| |
|6/24/2014||Peter A Md Demopulos||Director||Buy||6,153||$16.20||$99,678.60|| |
|6/2/2014||Thomas J Cable||Director||Sell||5,000||$11.80||$59,000.00|| |
|7/3/2013||Thomas J Cable||Director||Sell||5,000||$5.21||$26,050.00|| |
|4/10/2013||Thomas J Cable||Director||Sell||5,000||$3.98||$19,900.00|| |
|1/4/2013||Ray Aspiri||Director||Buy||40,000||$5.72||$228,800.00|| |
|1/3/2013||Arnold C Hanish||Director||Buy||2,000||$5.58||$11,160.00|| |
Omeros (NASDAQ OMER) News Headlines
Omeros (NASDAQ:OMER) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Omeros (NASDAQ:OMER) Income Statement, Balance Sheet and Cash Flow Statement
Omeros (NASDAQ OMER) Stock Chart for Wednesday, March, 21, 2018